Advanced search
Publication Cover
Therapeutics and Clinical Risk Management Volume 16, 2020 - Issue
Submit an article Journal homepage
151
Views
7
CrossRef citations to date
0
Altmetric
Review

Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis

Charlotte Näslund-Koch1 Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen, DenmarkORCID Iconhttps://orcid.org/0000-0003-2414-3076
ORCID Icon,
Claus Zachariae1 Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen, Denmark;2 Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5506-1319
ORCID Icon &
Lone Skov1 Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen, Denmark;2 Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkORCID Iconhttps://orcid.org/0000-0002-4784-9680
ORCID Icon
Pages 903-916 | Published online: 24 Sep 2020

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Albert Jang, Sree M. Lanka, Hui Ting Ruan, Hamsa L.S. Kumar, Angela Y. Jia, Jorge A. Garcia, Omar Y. Mian & Pedro C. Barata. (2023) Novel therapies for metastatic prostate cancer. Expert Review of Anticancer Therapy 23:12, pages 1251-1263.
Read now
Angelo Ruggiero, Elisa Camela, Luca Potestio, Gabriella Fabbrocini & Matteo Megna. (2022) Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge. Expert Opinion on Drug Safety 21:12, pages 1445-1451.
Read now
Marco Galluzzo, Andrea Chiricozzi, Elisa Cinotti, Giovanna Brunasso, Maurizio Congedo, Maria Esposito, Chiara Franchi, Giovanna Malara, Alessandra Narcisi, Stefano Piaserico, Rossana Tiberio, Giuseppe Argenziano, Gabriella Fabbrocini & Aurora Parodi. (2022) Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations. Expert Opinion on Biological Therapy 22:3, pages 367-376.
Read now

Articles from other publishers (4)

Gabrielle Becher, Sophia Conner, Jennifer A. Ingram, Karen E. Stephen, Alison C. McInnes, Adrian H. Heald, Paul A. Riley, Mark Davies, Arnau Domenech & Ismail Kasujee. (2022) A Retrospective Real-World Study of the Effectiveness and Tolerability of Tildrakizumab in UK Adults with Moderate-to-Severe Chronic Plaque Psoriasis. Dermatology and Therapy 12:10, pages 2343-2354.
Crossref
Nancy W. Wei, Sunny Chi & Mark G Lebwohl. (2022) Retrospective Analysis in Patients With Moderate to Severe Plaque Psoriasis Treated With Tildrakizumab: Real-Life Clinical Data. Journal of Psoriasis and Psoriatic Arthritis 7:2, pages 55-59.
Crossref
Gerardo J. Russo, Olga Marushchak & Mark G. Lebwohl. (2021) Psoriasis medications: The future. Dermatological Reviews 2:5, pages 296-305.
Crossref
Matteo Megna, Luca Potestio, Gabriella Fabbrocini & Eleonora Cinelli. (2021) Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?. Dermatologic Therapy 34:5.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.